Table 1—

Effects of fenofibrate in 46 hypertryglyceridemic patients

VariablesPlaceboFenofibratePercent changes
BMI (kg/m2)25.62 ± 0.40 (2.75)25.61 ± 0.40 (2.75)
Lipids (mg/dl)
    Total cholesterol234 ± 7 (50)204 ± 5 (35)*−11 ± 2 (15)*
    Triglycerides278 ± 15 (105)134 ± 9 (59)*−47 ± 4 (28)*
    LDL cholesterol134 ± 8 (52)122 ± 5 (34)1 ± 6 (39)
    Apolipoprotein B131 ± 4 (28)101 ± 3 (22)*−21 ± 3 (18)*
    HDL cholesterol45 ± 1 (9)55 ± 2 (12)*25 ± 4 (24)*
    Apolipoprotein A-I153 ± 3 (20)168 ± 4 (28)*9 ± 2 (13)*
    Non-HDL cholesterol190 ± 7 (48)149 ± 5 (36)*−19 ± 3 (18)*
Vasomotor function
    Brachial artery diameter (mm)
Basal 13.67 ± 0.07 (0.45)3.65 ± 0.06 (0.42)0 ± 1 (7)
Hyperemia3.83 ± 0.07 (0.46)3.89 ± 0.07 (0.45)2 ± 1 (7)
Basal 23.69 ± 0.07 (0.45)3.68 ± 0.06 (0.44)0 ± 1 (8)
Nitroglycerin4.16 ± 0.07 (0.50)4.23 ± 0.07 (0.50)2 ± 1 (7)
    Flow-mediated dilation (%)4.54 ± 0.19 (1.30)6.40 ± 0.19 (1.29)*48 ± 5 (34)*
    Nitroglycerin dilation (%)12.78 ± 0.45 (3.05)13.39 ± 0.52 (3.57)7 ± 3 (23)
    Fibrinogen (mg/dl)281 ± 10 (72)230 ± 9 (61)*−16 ± 3 (21)*
    CRP (mg/l)0.80 (0.50–2.50)0.70 (0.40–1.20)*18 ± 34 (233)*
Insulin resistance
    ADP (μg/ml)3.21 (2.62–4.92)3.54 (2.64–5.13)14 ± 5 (37)
    Insulin (μU/ml)3.52 ± 0.33 (2.24)3.10 ± 0.44 (2.99)−1 ± 11 (75)
    Glucose (mg/dl)89 ± 4 (26)88 ± 3 (23)1 ± 3 (19)
    QUICKI0.430 ± 0.011 (0.072)0.449 ± 0.010 (0.069)6 ± 2 (14)
  • Data are means ± SE (SD) or median (25th–75th percentile).

  • *

    * P < 0.001 vs. placebo,

  • P < 0.01,

  • P < 0.05. After testing data for normality, we used Student’s paired t or Wilcoxon signed rank test to compare the relative changes in values in response to placebo and fenofibrate treatments. Non-HDL cholesterol = total cholesterol − HDL cholesterol. QUICKI = 1/[log(insulin) + log(glucose)] (8).